N-Myc-mediated epigenetic reprogramming in advanced prostate cancer: personalized medicine and quality of biological samples

Saverio Bettuzzi


Prostate cancer (PCa) is a health issue, but also a great scientific challenge. The latency of PCa is very long. A population-based study in Sweden showed a PCA-specific death rate of 1% over the 10 years after diagnosis of low-risk PCA in men 70 years old at diagnosis, and lower rates for men younger at diagnosis (1,2). We do not understand why: the behavior of PCa and its progression are still difficult to predict.